Xcout IntelBCAL DIAGNOSTICS LIMITED competitors & alternatives
The 12 closest competitors and alternatives to BCAL DIAGNOSTICS LIMITED among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what BCAL DIAGNOSTICS LIMITED actually does, not by market-cap band.
Subscribe to see BCAL DIAGNOSTICS LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About BCAL DIAGNOSTICS LIMITED
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
BCAL DIAGNOSTICS LIMITED at a glance
BCAL DIAGNOSTICS LIMITED is a pharmaceuticals, biotechnology & life sciences company headquartered in Sydney, Australia. Xcout tracks 20 named people at BCAL DIAGNOSTICS LIMITED, including Thomas E. Polen Jr. (President, Chief Executive Officer & Chairman).
BCAL DIAGNOSTICS LIMITED leadership
- Thomas E. Polen Jr.President, Chief Executive Officer & Chairman
- Anne-Louise (Annie) ArnettChief Executive Officer
- Vitor RoqueExecutive Vice President & Chief Financial Officer
- Guy RobertsonChief Financial Officer & Company Secretary
- Elizabeth McCombsExecutive Vice President & Chief Technology Officer
- Michael C. FeldExecutive VP & Chief Revenue Officer
14 more named people on record for BCAL DIAGNOSTICS LIMITED, with roles, board committees and tenure — see the full roster →
Top 12 BCAL DIAGNOSTICS LIMITED competitors
Ranked by semantic similarity — how close each company is to BCAL DIAGNOSTICS LIMITED by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals, biotechnology & life sciences company
Genetic Technologies Limited (GTG.AX), an Australian molecular diagnostics company founded in Fitzroy in 1987, delivers predictive genetic testing and risk assessment tools. These solutions empower medical professionals in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific to proactively manage patient health. The company operates through two distinct divisions: EasyDNA and GeneType/Corporate. Among its offerings is BREVAGenplus, a clinically validated test specifically designed for assessing the risk of non-hereditary breast cancer. This product is actively promoted to healthcare providers such as obstetricians/gynecologists, breast surgeons, and specialists in breast health and imaging centers. GTG.AX also provides an array of cancer risk assessment tests, notably GeneType for Colorectal Cancer and GeneType for Breast Cancer, and is currently developing new risk assessments for conditions including ovarian cancer, prostate cancer, coronary artery disease, and type 2 diabetes. In addition to its diagnostic services, the company offers broader genetic testing solutions spanning medical, animal, forensic, and plant applications. Genetic Technologies Limited has established research and collaboration agreements with several prominent institutions, including the University of Melbourne, Translational Genomics Research Institute, and Memorial Sloan Kettering New York Cambridge University.
Similar pharmaceuticals, biotechnology & life sciences company
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Pacific Edge Ltd is a biotechnology research company headquartered in Dunedin, New Zealand, specializing in genomic diagnostics and the commercialization of the Cxbladder family of tests.
Similar pharmaceuticals, biotechnology & life sciences company
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.
Pharmaceuticals
Beroni Group Limited, established in 2014 and based in Sydney, Australia, is a global enterprise operating in China, Australia, the United States, and Japan. The company specializes in the creation and distribution of a diverse portfolio of health and wellness products. Its offerings span several key areas: Smoking Harm Reduction: This includes products like NicoBloc, designed to aid in smoking cessation. Environmental Quality: Beroni provides air purification systems, such as Fogibloc, and water filtration solutions under the Olansi brand. Health and Wellness: The company supplies a variety of health supplements and also markets cosmetic products, including V show rejuvenation liquids and various hyaluronic acid and avocado-based intensive treatment masks. Stem cell-derived cosmetic products are also part of its range. Diagnostic Tools: Beroni is active in the diagnostics field, offering detection kits for viruses like the SARS-CoV-2 IgG/IgM antibody kit for COVID-19, as well as the CII-ArboViroPlex rRT-PCR assay, which identifies arboviruses such as Zika, Dengue, Chikungunya, and West Nile. Beyond product sales, Beroni Group is heavily invested in research and development. Its R&D efforts focus on discovering and developing novel pharmaceutical drugs, conducting clinical trials, and advancing anti-cancer therapies. The company also provides services in gene detection and diagnosis, infectious disease diagnostics, and offers cell therapies for both cancer treatment and anti-aging applications. Furthermore, Beroni manages an e-commerce platform dedicated to pharmaceutical and healthcare products.
Healthcare Technology
Person Health Inc. provides a preventive health-intelligence platform that combines differentiated diagnostics, person-centered data, and guided engagement to help clinicians and researchers recognize health risks earlier. Its initial focus is a research-use-only program centered on breast cancer detection using blood-based molecular fingerprinting, with plans to expand to non-invasive breath technologies and other diseases.
Healthcare
AOA Dx Inc. is a US-based diagnostics biotechnology company with offices in Boston, New York, and London, focusing on the early detection of ovarian cancer.
Healthcare
EarlyDiagnostics, also known as EarlyDx, is a clinical-stage precision diagnostics company that develops non-invasive liquid biopsy technologies and genomics platforms for early cancer detection.
Biotechnology
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
Biotechnology
Reveal Genomics, S.L. is a biotechnology company founded in 2020 and headquartered in Barcelona, Spain. The company develops innovative genomic tools to improve breast cancer treatment and personalized medicine.
Biotechnology
ExosomeDx (Exosome Diagnostics) develops noninvasive liquid-biopsy diagnostics based on RNA carried in exosomes, including the ExoDx Prostate test for assessing prostate-cancer risk. Its products serve urologists, oncologists, laboratories, and patients by supporting clinical decision-making without relying solely on invasive biopsy.
Diagnostics
Exosome Diagnostics, Inc. is a molecular diagnostics company located in Massachusetts, United States. The company specializes in developing biofluid-based liquid biopsy tests, such as the ExoDx Prostate test, for use in personalized medicine and oncology.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of BCAL DIAGNOSTICS LIMITED and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BCAL DIAGNOSTICS LIMITEDand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →